iCAD to Showcase Its Platform of Computer-Aided Detection and Advanced Imaging Solutions at RSNA Annual Meeting

  iCAD to Showcase Its Platform of Computer-Aided Detection and Advanced
  Imaging Solutions at RSNA Annual Meeting

RSNA 2013

Business Wire

NASHUA, N.H. & CHICAGO -- November 26, 2013

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced that the Company will
showcase its suite of Computer-Aided Detection (CAD) and advanced imaging
solutions at the Radiological Society of North America (RSNA) 99^th Annual
Meeting being held December 1-6, 2013 in Chicago. iCAD will feature the
SecondLook^® CAD technology for the identification of breast cancer, including
the PowerLook^® Advanced Mammography Platform^® featuring iCAD partner
Mātakina’s VolparaDensity volumetric breast density assessment software.
iCAD’s VeraLook^®, a revolutionary CAD solution for virtual colonoscopy (CTC)
designed to enhance clinician accuracy and effectiveness by improving
detection of colonic polyps, will also be on display.

“The robust display of CAD and imaging solutions showcased in our booth at
this year’s RSNA are a testament to iCAD’s proven history and long-time
leadership position in the radiology space,” said Ken Ferry, President and CEO
of iCAD. “iCAD remains committed to the continued development of advanced
technologies, like CAD for 3D tomosynthesis, to meet the needs of our more
than 4,800 customers as well as delivering cost-effective, innovative
solutions that help radiologists detect cancers with greater confidence.”

iCAD offers high-performance, upgradeable CAD systems and workflow solutions
for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography
(CT). PowerLook AMP provides radiologists with the ability to customize their
CAD solution to meet the needs of their individual work environment, including
the integration of Mātakina’s VolparaDensity assessment solution, an
FDA-cleared technologic advancement providing volumetric breast density
measurements that correlate to the BI-RADS breast density category to assist
in interpreting digital mammograms. The technology expands on iCAD’s
SecondLook Digital algorithm and the CAD metrics feature provides a rich set
of clinical decision support tools to aid in mammography screening. Shown to
be effective in the detection of colonic polyps, iCAD’s VeraLook CAD solution
is designed to integrate with specialized CTC reading environments to
streamline the reading process and improve clinician accuracy, productivity,
and workflow.

iCAD also recognizes the importance of 3D tomosynthesis to the diagnosis of
breast cancer. This technology provides radiologists with an unprecedented
amount of data to aid in their diagnosis. In order to efficiently utilize this
amount of information, radiologists need additional tools to streamline their
workflow. iCAD is working closely with several of its OEM partners to design
and develop a robust CAD solution specifically for tomosynthesis that will
optimize workflow for the radiologists by making it easier to detect regions
of interest. At RSNA 2013, iCAD will display its latest version of this
technology as a “works in progress.”

In addition to a presence in the Invivo Corporation’s booth (#2700 in South
Building, Hall A), DynaCAD, iCAD’s MRI product suite for quantification image
analysis of the breast, prostate and other organs, will also be featured in a
Scientific Formal Presentation taking place on Friday, December 6 from 10:30
a.m. to 12:00 p.m. in Room N230 in the North Building. The session will
discuss “Tumor Cellularity and the Extravascular-Extracellular Space: Using
Quantitative Imaging to Evaluate Correlation Between ADC and DCE MRI in Human
Gliomas, Meningiomas and Cerebral Lymphomas,” a study co-authored by Naira
Muradyan, PhD, Lead Senior Research Scientist, iCAD, Inc., which may provide
new imaging biomarkers of brain tumor cellularity.

For additional information regarding iCAD and the technologies on display at
RSNA 2013, please visit http://www.icadmed.com/newsevents/rsna2013.htm.

About the Radiological Society of North America (RSNA)
RSNA is an association of more than 53,000 radiologists, radiation
oncologists, medical physicists and related scientists, promoting excellence
in patient care and health care delivery through education, research and
technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)

About iCAD, Inc.
iCAD is an industry-leading provider of Computer-Aided Detection (CAD)
technologies, advanced image analysis, workflow solutions and radiation
therapies for the early identification and treatment of common cancers. iCAD
offers a comprehensive range of high-performance, upgradeable CAD solutions
for mammography and advanced image analysis and workflow solutions for
Magnetic Resonance Imaging, for breast and prostate cancers and Computed
Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation
treatment for early-stage breast cancer that can be administered in the form
of Intraoperative Radiation Therapy or accelerated partial breast irradiation.
The Xoft System is also cleared for the treatment of non-melanoma skin cancer
and gynecological cancers. For more information, call (877) iCADnow, or visit

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the Company’s
ability to identify a replacement for the Axxent FlexiShield Mini, the risks
relating to the Company’s acquisition of Xoft including, the expected benefits
of the acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at


For iCAD
Kevin Burns, 937-431-7967
For iCAD investor relations
Anne Marie Fields, 212-838-3777 x6604
For iCAD media inquiries
Schwartz MSL
Rachel Gross, 781-684-0770
Press spacebar to pause and continue. Press esc to stop.